Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Going Concern and Plan of Operation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ (23,187,164)	$ (14,051,764)
Net loss	$ (9,135,400)	$ (10,221,045)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.